Advertisement

Dr Reddy's launches generic cancer drug in India

Follow The Hawk on Google News+ Follow

Advertisement


New Delhi: Dr Reddy's Laboratories on Monday said it has launched blood cancer drug Invista in the country.

The company's product is a formulation of Dasatinib that is bioequivalent to the innovator brand, Dr Reddy's Laboratories said in a statement.

Advertisement

Patent on Dasatinib is owned by Bristol-Myers-Squibb. The Indian patent has expired on April 12, 2020.

Also readFSSAI to initiate action against Bisleri over unsafe water sample

Invista, which is available in strengths of 50, 70 and 100 mg tablets, is indicated for the treatment of primarily Chronic Myeloid Leukemia (CML).

CML is a type of blood-cell cancer that begins in the bone marrow.

Advertisement

The median age of the patients in India is a decade earlier than the west, and every year about nine thousand new patients are diagnosed in the country.

"The development and launch of Invista is a significant step forward in improving access to medicines at an affordable price for CML patients in India," Dr Reddy's Laboratories CEO, Branded Markets (India and Emerging Markets), M V Ramana said.

—PTI

Get The Hawk first on Google

Add The Hawk as a preferred source and Google shows you more of our stories in Top Stories. Follow us on Google News too.

Share this story

Advertisement

India eyes space-based drug development as scientists, startups explore microgravity researchRead next →India eyes space-based drug development as scientists, startups explore microgravity researchHealth · 22 Nov 2026, 03:08 PM IST